# Efficacy and Safety of EzetimiBe/Rosuvastatin in Diabetic Dislipidemia With Hypertriglyceridaemia

Study · id `cardio:ct-nct04700436` · Cardiovascular Atlas · release `a25293eeae6350fb` (public)

> General information from published sources, not medical advice, and not reviewed by clinicians. Check the cited source before relying on anything here. Sponsors do not influence what this atlas says.

The atlas's own text and curation may be reused under Creative Commons Attribution-NonCommercial 4.0 International (CC BY-NC 4.0, https://creativecommons.org/licenses/by-nc/4.0/): credit the atlas, and do not use it commercially without a licence from the owner. See the atlas About page. Text quoted from a source stays under that source's own terms, given as the source's reuse\_basis. The atlas's reuse terms do not cover it. The downloads list each quotation with its source in third\_party\_quotations.

**Registry record.** Assembled by a program from [ClinicalTrials.gov record NCT04700436](<https://clinicaltrials.gov/study/NCT04700436>), retrieved 26 October 2026. No person wrote or checked this page.

Also called: NCT04700436

Browse, organ or system: Metabolism  
Browse, condition area: Risk and prevention; Diabetes and metabolic disease  

## In plain language

A phase 4 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 146 participants.

## Technical summary

Registry record NCT04700436. Randomized; no masking; primary purpose treatment. Start 2020-01-03 (actual); primary completion 2021-05-28 (actual). Results not posted.

## Key facts

- Design: Interventional study; randomized; no masking; primary purpose treatment
- Phase: Phase 4
- Enrolled: 146 participants (enrolled count; ClinicalTrials.gov record NCT04700436, source copy `cardio:ctgov-nct04700436-2025-08-14`, retrieved 2026-10-26)
- Started: 2020-01-03 (actual) (ClinicalTrials.gov record NCT04700436, source copy `cardio:ctgov-nct04700436-2025-08-14`, retrieved 2026-10-26)
- Primary completion: 2021-05-28 (actual) (ClinicalTrials.gov record NCT04700436, source copy `cardio:ctgov-nct04700436-2025-08-14`, retrieved 2026-10-26)
- Completion: 2024-02-13 (actual) (ClinicalTrials.gov record NCT04700436, source copy `cardio:ctgov-nct04700436-2025-08-14`, retrieved 2026-10-26)
- Countries: South Korea (ClinicalTrials.gov record NCT04700436, source copy `cardio:ctgov-nct04700436-2025-08-14`, retrieved 2026-10-26)
- Care setting: Not reported
- Registry status: "COMPLETED" (U.S. National Library of Medicine (ClinicalTrials.gov), source copy `cardio:ctgov-nct04700436-2025-08-14`, retrieved 2026-10-26)

## The registry's words

- Brief title: Efficacy and Safety of EzetimiBe/Rosuvastatin in Diabetic Dislipidemia With Hypertriglyceridaemia
- Acronym: REMBRANDT
- Condition: Endocrine System Diseases
- Condition: Nutritional and Metabolic Diseases
- Condition: Diabetes Mellitus, Type 2
- Condition: Dyslipidemias
- Intervention (Drug): Rosuzet tablet 10/5 mg (Ezetimibe 10 mg/Rosuvastatin 5 mg)
- Intervention (Drug): Suvast tablet 10 mg (Rosuvastatin 10 mg)
- Lead sponsor: Seoul National University Hospital
- Lead sponsor class: OTHER
- Collaborator: Gangnam Severance Hospital
- Collaborator class: OTHER

## Connected pages

- Registry condition terms include this condition: Dyslipidemia (`cardio:dyslipidemia`)
- Registry condition terms include this condition: Type 2 diabetes (`cardio:type-2-diabetes`)
- Registry condition terms include this condition: Diabetes mellitus (`core:diabetes-mellitus`)
- Registry lists this organization as the lead sponsor: Seoul National University Hospital (`cardio:org-seoul-national-university-hospital`)
- Registry lists this organization as a collaborator: Gangnam Severance Hospital (`cardio:org-gangnam-severance-hospital`)

## Provenance

Content hash: 7d941adcf770f11a19e7d9f150dd2497a46cd0af495b42efa2b6f0f6c94f80d3
Last substantive edit: 2026-11-08
Evidence last checked: Not recorded
